⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
PRTA News
Prothena Corporation plc Ordinary Shares
Prothena Highlights Phase 2 Data for Coramitug (Formerly PRX004) Published in Circulation, Official Journal of AHA
businesswire.com
PRTA
Prothena to Report Third Quarter 2025 Financial Results on November 6
businesswire.com
PRTA
Prothena’s Partner Bristol Myers Squibb Obtains Fast Track Designation from the U.S. FDA for BMS-986446 (PRX005), an Anti-MTBR-Tau-Targeting Antibody, for the Treatment of Alzheimer’s Disease
businesswire.com
PRTA